Neuronetics Inc
NASDAQ:STIM
Net Margin
Neuronetics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Neuronetics Inc
NASDAQ:STIM
|
261.3m USD |
-54%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
229.2B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
198B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
155.2B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
145.6B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
104.4B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.8B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.7B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.2B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
41.6B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
279.5B CNY |
31%
|
Neuronetics Inc
Glance View
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Neuronetics Inc's most recent financial statements, the company has Net Margin of -54.2%.
You don't have any saved screeners yet